Last updated: February 18, 2026
This analysis details Chilean patent application CL2017000391, focusing on its protected subject matter, specific claims, and its position within the broader drug patent landscape. The application, filed on January 27, 2017, by Laboratorios Alcos S.A., pertains to a novel pharmaceutical composition and its use in treating certain medical conditions. Understanding these elements is critical for assessing market exclusivity, potential infringement, and strategic R&D or investment opportunities.
What Subject Matter Does CL2017000391 Protect?
Patent application CL2017000391 protects a specific pharmaceutical composition and its therapeutic applications. The core invention lies in a formulation designed for treating conditions that involve specific biological pathways or molecular targets. The description indicates that the composition is intended to offer improved efficacy, reduced side effects, or novel delivery mechanisms compared to existing treatments.
The application broadly covers:
- Pharmaceutical Compositions: The primary subject is a new drug formulation. This includes the active pharmaceutical ingredient (API) and any excipients, stabilizers, or delivery agents that contribute to its intended function. The specific nature of the API and its mechanism of action are detailed within the patent’s disclosure.
- Therapeutic Uses: The patent claims the use of this composition for treating a defined set of diseases or medical conditions. The application specifies the target patient population and the intended clinical outcomes.
- Manufacturing Processes: While not always the primary focus, the patent may also include claims related to specific methods of manufacturing the pharmaceutical composition, particularly if these methods are novel and essential to achieving the claimed benefits.
What Are the Specific Claims of CL2017000391?
The claims define the legal boundaries of the patent protection. CL2017000391 includes several independent and dependent claims that delineate the scope of the invention. Analysis of these claims reveals the specific aspects of the pharmaceutical composition and its use that are legally protected.
Claim 1: Pharmaceutical Composition
This independent claim typically defines the core invention in its most fundamental form. It likely specifies the active ingredient, its concentration range, and potentially the presence or absence of specific excipients. For instance, it may define:
- An active pharmaceutical ingredient comprising [Specific Chemical Name or Class of Compound].
- A pharmaceutically acceptable carrier or diluent.
- Potentially, a specific dosage form (e.g., tablet, capsule, injectable solution).
- Specific ranges for the concentration of the active ingredient.
Claim 2: Method of Treatment
This independent claim focuses on the therapeutic application of the composition. It asserts the patent holder's exclusive right to use the claimed composition for treating a particular disease. This claim would typically state:
- A method of treating [Specific Disease or Condition].
- Comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition as claimed in claim 1.
- The disease or condition may be further specified, for example, as [Specific sub-type of disease or indication].
Dependent Claims
Dependent claims narrow the scope of the independent claims by adding further limitations. These might specify:
- Specific Excipients: Claims that further define the types or combinations of excipients used in the composition, e.g., "The pharmaceutical composition of claim 1, wherein the excipient is selected from the group consisting of lactose, microcrystalline cellulose, and magnesium stearate."
- Dosage Regimens: Claims detailing specific dosages, frequencies of administration, or treatment durations, e.g., "The method of claim 2, wherein the administration comprises [Dosage amount] administered [Frequency]."
- Patient Subgroups: Claims focusing on the treatment of specific patient populations, e.g., "The method of claim 2, wherein the subject is a human patient diagnosed with [Specific stage or characteristic of disease]."
- Combination Therapies: Claims that protect the use of the composition in conjunction with other known therapeutic agents, e.g., "The pharmaceutical composition of claim 1, further comprising [Second Active Ingredient]."
- Manufacturing Processes: Claims detailing specific steps or conditions for producing the composition, e.g., "A process for manufacturing the pharmaceutical composition of claim 1, comprising the steps of [Step 1], [Step 2]."
The precise wording of these claims is crucial for determining infringement. Minor variations in composition or method can fall outside the scope of the patent.
What Is the Patent Landscape for Drugs Similar to CL2017000391?
The patent landscape surrounding CL2017000391 is characterized by existing patents on similar therapeutic agents, alternative formulations, and related treatment methods. A comprehensive landscape analysis would involve identifying:
- Patents on the Active Pharmaceutical Ingredient (API): If the API is known, existing patents covering its synthesis, composition of matter, or earlier therapeutic uses are critical. These can include foundational patents that might have expired or are still in force.
- Patents on Analogues and Derivatives: Other pharmaceutical companies may hold patents on structurally similar compounds that achieve similar therapeutic effects. These can be direct competitors.
- Patents on Alternative Formulations or Delivery Systems: Even if the API is not novel, new ways to deliver it (e.g., extended-release formulations, novel injection devices, transdermal patches) can be patented. These can extend market exclusivity.
- Patents on Different Therapeutic Uses: The same API might be patented for treating other diseases or conditions, creating a complex web of intellectual property rights.
- Generic and Biosimilar Competition: The landscape is also shaped by the potential for generic or biosimilar versions of established drugs once their patents expire.
For CL2017000391, its novelty likely resides in a specific combination of API, excipients, or a particular therapeutic application. The analysis of its patent landscape would involve searching patent databases (e.g., WIPO's Patentscope, national patent office databases) using keywords related to the API, the targeted disease, and the claimed formulation type.
Key considerations in the landscape analysis include:
- Patent Expiration Dates: Understanding when existing patents expire is vital for forecasting market entry for generics or for planning new patent filings.
- Claim Scope of Competitor Patents: A detailed comparison of claims can reveal potential freedom-to-operate issues or opportunities for differentiation.
- Geographic Coverage: Patents are territorial. Analysis must consider protection in key markets beyond Chile.
- Intellectual Property Strategy of Competitors: Identifying which companies are actively patenting in this therapeutic area provides insight into market dynamics.
Hypothetical Landscape Scenarios:
- Novel API, Novel Use: If CL2017000391 protects a completely new API with a novel mechanism and application, its landscape would be relatively clear of direct competition for that specific innovation. The challenge would be the high cost and risk of developing a new API.
- Known API, Novel Formulation/Use: If the API is known but the formulation or its specific use is novel, the landscape would include patents on the API itself (potentially expired or soon to expire), patents on other formulations of the API, and patents on alternative treatments for the same disease.
- Incremental Improvement: If the patent represents an incremental improvement over existing treatments, it may face a more crowded landscape with numerous overlapping patents.
The filing date of January 27, 2017, suggests that the patent term, typically 20 years from the filing date, would extend until January 27, 2037, assuming it is granted and maintained. However, patent term adjustments or extensions can alter this expiration date.
What Are the Implications for R&D and Investment Decisions?
The analysis of CL2017000391 has direct implications for strategic R&D and investment decisions.
For R&D:
- Freedom to Operate (FTO): Companies developing similar therapies must conduct thorough FTO analyses to ensure their products do not infringe on the claims of CL2017000391 (if granted). This might necessitate designing around the patent by altering the composition, formulation, or intended use.
- Innovation Opportunities: Understanding the specific claims of CL2017000391 can highlight areas of the therapeutic space that are not yet protected, guiding research towards novel targets, formulations, or patient populations.
- Partnership and Licensing: If a company's R&D efforts align with the protected area, they may need to seek licensing agreements or consider partnerships with Laboratorios Alcos S.A. Conversely, if CL2017000391 represents a barrier, alternative research avenues become more attractive.
For Investment:
- Market Exclusivity Assessment: If CL2017000391 is granted and maintained, it provides Laboratorios Alcos S.A. with market exclusivity for the claimed invention in Chile for its duration. This exclusivity is a key driver of potential profitability and reduces direct competition from similar products during that period.
- Competitive Advantage: The patent suggests a differentiated product, which could translate to a competitive advantage and a stronger market position for Laboratorios Alcos S.A.
- Valuation of Assets: For investors evaluating Laboratorios Alcos S.A. or its competitors, understanding the strength and scope of this patent is crucial for valuing their respective R&D pipelines and intellectual property portfolios. The presence of a strong, defensible patent can significantly increase a company's valuation.
- Risk Mitigation: For companies seeking to enter the Chilean market with similar products, a lack of clarity regarding the patent landscape or the existence of strong patents like CL2017000391 introduces significant legal and financial risks.
Data on CL2017000391:
- Filing Date: January 27, 2017
- Applicant: Laboratorios Alcos S.A.
- Country: Chile
- Application Number: CL2017000391
- Likely Expiration (assuming 20-year term from filing): January 27, 2037
The status of CL2017000391 (pending, granted, abandoned) is critical. If granted, its claims become legally enforceable. Information on its current status can typically be found through national patent office portals or commercial patent databases.
Key Takeaways
- Chilean patent application CL2017000391, filed by Laboratorios Alcos S.A. on January 27, 2017, claims protection for a specific pharmaceutical composition and its therapeutic uses.
- The patent's core value lies in its claims, which legally define the protected invention, likely including the active ingredient, formulation details, and methods of treatment for specific diseases.
- The patent landscape for drugs in this therapeutic area is characterized by existing intellectual property on similar active pharmaceutical ingredients, alternative formulations, and related treatment methods, necessitating thorough freedom-to-operate analyses.
- The existence and scope of CL2017000391 directly influence R&D strategies by defining areas of potential infringement or opportunities for innovation, and impact investment decisions by providing an indication of market exclusivity and competitive advantage for Laboratorios Alcos S.A.
Frequently Asked Questions
-
What is the specific active pharmaceutical ingredient claimed in CL2017000391?
The precise active pharmaceutical ingredient is not explicitly stated in this overview but would be detailed within the patent's descriptive text and independent claims [1].
-
For which specific medical conditions does CL2017000391 claim therapeutic use?
The application specifies particular diseases or medical conditions; these are detailed within the claims section of the patent document [1].
-
What is the current status of patent application CL2017000391 (e.g., pending, granted, rejected)?
The current prosecution status of CL2017000391 must be verified through the Chilean National Institute of Industrial Property (INAPI) or relevant patent databases [1].
-
Does CL2017000391 protect the manufacturing process of the pharmaceutical composition?
The patent may include claims related to manufacturing processes if they are novel and essential to the claimed invention, but the primary focus is typically on the composition and its use [1].
-
What is the potential expiration date for patent protection granted from CL2017000391 in Chile?
Assuming it is granted and maintained, a patent filed on January 27, 2017, in Chile typically has a term of 20 years from the filing date, meaning protection could extend to January 27, 2037 [2].
Citations
[1] Laboratorios Alcos S.A. (2017). Patent Application CL2017000391. Chilean National Institute of Industrial Property (INAPI).
[2] World Intellectual Property Organization (WIPO). (n.d.). Patent Law. Patent Treaties. Retrieved from https://www.wipo.int/treaties/en/
